Dan Menold | Vice President, Finance |
Sujal Shah | President and Chief Executive Officer |
Charles McWherter | Senior Vice President and Chief Scientific Officer |
Klara Dickinson | Chief Regulatory and Compliance Officer |
Chuck McWherter | Chief Scientific Officer |
Dr. Paul Watkins | Chair of Expert Review Panel |
Dr. David Kleiner | Head of the Drug-Induced Liver Injury Network at NIH |
Dr. Stephen Harrison | Principal Investigator NASH Program |
Yasmeen Rahimi | ROTH Capital Partners |
Eliana Merle | Cantor Fitzgerald |
Steve Seedhouse | Raymond James |
Jay Olson | Oppenheimer & Co Inc. |
Shawn Egan | Citigroup |
Welcome to the CymaBay Therapeutics' First Quarter 2020 Earnings Conference Call.
As a reminder, all participants are in listen-only mode and the conference is being recorded. [Operator Instructions]
I would now like to turn the conference over to Mr. Dan Menold, Vice President of Finance.